Session Information
Date: Sunday, November 8, 2015
Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: Systemic scleroderma (SSc) is a generalized connective tissue disease characterized by fibrosis of the skin and internal organs, vascular dysfunction and immune disorder. Patients with SSc typically develop Raynaud’s phenomenon (RP) and persistent digital ischemia, and often develop digital ulcers (DU). Currently, there is no satisfactory treatments for RP in SSc. Recently, it was reported that botulinum toxin A (BTX-A) injection was effective for the treatment of RP in SSc patients. Objective was to assess the efficacy and safety of BTX-A on RP in Japanese SSc patients.
Methods: In the prospective, open-label trial, 10 Japanese SSc patients with RP received 10U of BTX-A injections into the hand. The change in severity of RP, including the frequency of attacks/pain, color changes, duration time of RP and the severity of pain was assessed by the Raynaud score and pain VAS at each visits during 16 weeks. The recovery of skin temperature 20 minutes after cold-water stimulation was examined by thermography at baseline and 4 weeks after injection. The number of DU and adverse events were assessed at each visits.
Results: BTX-A injection decreased Raynaud’s score and pain VAS from 2 weeks after injection, and the suppressive effect was continued until 16 weeks after injection. The symptoms of RP in 10 SSc patients without BTX-A treatment remained unchanged 4 weeks after injection, however, those in 10 patients with BTX-A injection were significantly improved. Skin temperature recovery after cold-water stimulation at 4 weeks after injection was significantly elevated compared to that before injection. All DU in five patients were healed within 12 weeks after injection. Neither systemic nor local adverse events was observed in all patients.
Conclusion: We conclude that BTX-A injection significantly improved the activity of RP in SSc patients without any adverse events, suggesting that BTX-A might have possible long-term preventive and therapeutic potentials for RP and RP-related DU in Japanese SSc patients.
To cite this abstract in AMA style:
Motegi SI, Yamada K, Toki S, Uchiyama A, Nakamura T, Ishikawa O. Beneficial Effect of Botulinum Toxin-a on Raynaud’s Phenomenon in Japanese Patients with Systemic Sclerosis: A Prospective, Open-Label Trial [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/beneficial-effect-of-botulinum-toxin-a-on-raynauds-phenomenon-in-japanese-patients-with-systemic-sclerosis-a-prospective-open-label-trial/. Accessed .« Back to 2015 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/beneficial-effect-of-botulinum-toxin-a-on-raynauds-phenomenon-in-japanese-patients-with-systemic-sclerosis-a-prospective-open-label-trial/